Reviticell Revenue

About Reviticell

Reviticell is a dynamic company that has leveraged the brilliance of doctors, scientists and industry experts to create a revolutionary new approach for the preparation of medical treatments. The Reviticell System is a sophisticated, but elegantly simple device, that can accomplish what would otherwise require a laboratory and clinicians at an institution like Mayo Clinic. If you had an orthopedic problem, you could get a shot of Cortisone, but that wouldn't really fix the underlying problem. A better option would be for your doctor to prepare some of your blood or tissue using the Reviticell System to create your treatment. This non-pharmaceutical approach for treating you is called regenerative medicine and it's driving a huge emerging market. In fact, even in its infancy, it's more than a 50 billion-dollar industry. What's unique about regenerative medicine is that, not only do doctors have to treat their patients, but, first, they have to prepare their patients' treatments, while they are under anesthesia and laying there waiting. As you can imagine, this adds a level of complexity to what's already going on in the operating room, not to mention significant risk to the patient as the clock continues to tick. Worse yet, doctors who practice regenerative medicine are completely dissatisfied because, until now, there hasn’t been a single medical-device they can use to efficiently prepare regenerative treatments with consistent and effective outcomes. Unlike the inferior devices currently being marketed, the patented Reviticell System enables the efficient and precise preparation of regenerative treatments, because it's configured with a sequence of modular cartridges that each contain the exact components necessary to prepare a specific medical treatment, in accordance with a proprietary protocol. This is what makes producing consistent and effective outcomes possible. Prospective investors, please email investor-relations@reviticell.com.

View contact profiles from Reviticell